Q4 EPS Estimate for Corcept Therapeutics Lifted by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Research analysts at HC Wainwright increased their Q4 2026 EPS estimates for shares of Corcept Therapeutics in a report issued on Thursday, January 22nd. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of $0.81 for the quarter, up from their prior estimate of $0.74. HC Wainwright currently has a “Buy” rating and a $105.00 target price on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share.

CORT has been the subject of a number of other research reports. Zacks Research lowered Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research note on Friday. UBS Group assumed coverage on shares of Corcept Therapeutics in a research note on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 target price for the company. Finally, Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target for the company. in a report on Wednesday, December 31st. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $83.50.

Corcept Therapeutics Price Performance

Corcept Therapeutics stock opened at $43.98 on Monday. Corcept Therapeutics has a 1 year low of $32.99 and a 1 year high of $117.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.14. The firm has a 50 day moving average price of $65.24 and a 200 day moving average price of $71.12. The company has a market cap of $4.63 billion, a price-to-earnings ratio of 49.98 and a beta of 0.23.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). The business had revenue of $207.64 million for the quarter, compared to analysts’ expectations of $223.78 million. Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.41 EPS.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, insider Joseph Douglas Lyon sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $73.65, for a total transaction of $368,250.00. Following the transaction, the insider directly owned 10,277 shares in the company, valued at $756,901.05. This trade represents a 32.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Sean Maduck sold 20,000 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $79.52, for a total value of $1,590,400.00. Following the transaction, the insider directly owned 7,904 shares in the company, valued at approximately $628,526.08. This represents a 71.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 194,500 shares of company stock worth $14,186,410. 20.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Corcept Therapeutics

Several large investors have recently made changes to their positions in the business. Advisory Services Network LLC acquired a new position in shares of Corcept Therapeutics in the 3rd quarter valued at $25,000. Clearstead Advisors LLC lifted its stake in Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 193 shares during the period. Golden State Wealth Management LLC bought a new position in Corcept Therapeutics during the second quarter worth about $28,000. Huntington National Bank boosted its holdings in Corcept Therapeutics by 54.0% during the second quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 168 shares in the last quarter. Finally, Hantz Financial Services Inc. grew its stake in shares of Corcept Therapeutics by 598.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 395 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Phase 3 ROSELLA met its overall survival primary endpoint in platinum‑resistant ovarian cancer — a clear clinical success that materially improves relacorilant’s value thesis and is the main driver of the move. Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
• Positive Sentiment: Multiple trade and analyst outlets reported the OS win, reinforcing market confidence that the drug could drive future revenue and partnership interest. CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study
• Positive Sentiment: Wall‑street coverage (e.g., Reuters) flagged the late‑stage success, increasing visibility with institutional investors and media, which can amplify buying interest. Corcept’s cancer drug meets main goal in late-stage trial
• Positive Sentiment: Analyst optimism picked up: Canaccord raised its price target to $100 and maintained a buy rating, signaling upside potential versus the current price and likely supporting additional demand. CORT Corcept Therapeutics price target raised by Canaccord
• Neutral Sentiment: Options flow shows elevated activity: about 4,870 put contracts were purchased (≈78% above the typical daily put volume), indicating some investors are hedging or speculating on near‑term volatility rather than a clear directional consensus. (No external link)
• Negative Sentiment: Regulatory and legal overhangs remain — shareholder law firms (Hagens Berman and Pomerantz) launched investigations tied to the company’s prior FDA complete response letter for relacorilant in Cushing’s syndrome and the sharp December sell‑off, which could lead to litigation costs or disclosure risk. CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
• Negative Sentiment: Remember the December FDA complete response letter for relacorilant (Cushing’s syndrome) that previously drove a large share price drop — regulatory uncertainty remains a material risk even after the oncology win. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated – CORT

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.